BioTuesdays

Author - Leonard Zehr

Achillion Logo
Markets

Leerink upgrades Achillion to OP

Leerink upgraded Achillion Pharmaceuticals (NASDAQ:ACHN) to “outperform” from “market perform” and raised its price target to $6 from $4. The stock closed at $3.78 on May 17. Achillion has a portfolio of direct...

May 18, 2017
Quidel
Developments

Quidel acquires InflammaDry and AdenoPlus

Quidel (NASDAQ:QDEL) has acquired the InflammaDry and AdenoPlus diagnostic businesses from RPS Diagnostics for about $14-million. InflammaDry is the only point-of-care test that detects elevated levels of MMP-9, a key...

May 17, 2017
T2 Biosystems Logo
Markets

BTIG ups T2 Biosystems to neutral

BTIG upgraded T2 Biosystems (NASDAQ:TTOO) to “neutral” from “sell,” saying the shares have fallen below a prior $4 price target. The stock closed at $3.98 on May 5. “While there is no change to our thesis on T2Candida...

May 8, 2017
Intra Cellular Therapies
Markets

Leerink cuts Intra-Cellular Therapies to MP

Leerink downgraded Intra-Cellular Therapies (NASDAQ:ITCI) to “market perform” from “outperform” and slashed its price target to $10 from $29, following a corporate update highlighting an unusual preclinical safety...

May 2, 2017
Feature

3DS’ genomic imaging for precision medicine

By Len Zehr As CEO of 3D Signatures (OTCQB:TDSGF; TSXV:DXD; FSE:3D0) since last September, Jason Flowerday is putting the diagnostic company on people’s radar. Unlike most diagnostic companies, 3DS’ proprietary imaging...

May 2, 2017
3D Signatures
Developments

3DS processes first samples from PRECISE trial

3D Signatures (TSXV:DXD; OTCQB:TDSGF; FSE:3D0) has processed and analyzed the first batch of blood samples for the PRECISE prostate cancer trial at its new laboratory and corporate headquarters in the MaRS Discovery...

April 27, 2017